Top

Gepubliceerd in:

2021 | OriginalPaper | Hoofdstuk

15. Stoornis in het gebruik van een middel

Auteurs : Drs. Maarten Belgers, Prof. dr. Arnt Schellekens

Gepubliceerd in: Ernstige psychiatrische aandoeningen

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

Verslaving kan zich ontwikkelen tot een ernstige psychiatrische aandoening. Mensen met EPA hebben vaak een comorbide stoornis in het gebruik van een of meerdere middelen. De symptomatologie is niet altijd eenduidig naar een oorzaak te herleiden vanwege verschil in symptomatologie tijdens acuut en chronisch gebruik en onthouding van middelen, en de overlap en interactie met deze symptomatologie en overige psychische en somatische morbiditeit. Juiste diagnostiek is hierdoor uitdagend en behandeling van deze patiëntengroep is overwegend intensief en zal multidisciplinair uitgevoerd moeten worden. De sterk verhoogde mortaliteit en morbiditeit en het verminderd welzijn bij deze groep onderstreept de noodzaak van een adequate behandeling.

vorige hoofdstuk Zwakbegaafdheid, lichte verstandelijke beperking en EPA

volgende hoofdstuk De impact van traumatisering in de kindertijd en PTSS bij mensen met psychotische en andere ernstige psychiatrische aandoeningen

Brook, J. S., Zhang, C., Rubenstone, E., Primack, B. A., & Brook, D. W. (2016). Comorbid trajectories of substance use as predictors of antisocial personality disorder, major depressive episode, and generalized anxiety disorder. Addictive Behaviors, 62, 114–121.PubMedPubMedCentralCrossRef

Buckley, P. F. (2006). Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. Journal of Clinical Psychiatry, 67(Suppl 7), 5–9.

Chan, Y. F., Dennis, M. L., & Funk, R. R. (2008). Prevalence and comorbidity of major internalizing and externalizing problems among adolescents and adults presenting to substance abuse treatment. Journal of Substance Abuse Treatment, 34(1), 14–24.PubMedCrossRef

Clausen, H., Ruud, T., Odden, S., Saltyte Benth, J., Heiervang, K. S., Stuen, H. K., et al. (2016). Hospitalisation of severely mentally ill patients with and without problematic substance use before and during assertive community treatment: An observational cohort study. BMC Psychiatry, 16, 125.PubMedPubMedCentralCrossRef

De Andrade, D., Elphinston, R. A., Quinn, C., Allan, J., & Hides, L. (2019). The effectiveness of residential treatment services for individuals with substance use disorders: A systematic review. Drug and Alcohol Dependence, 201, 227–235.PubMedCrossRef

De Leon, J., & Diaz, F. J. (2005). A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research, 76(2–3), 135–157.PubMedCrossRef

De Ruysscher, C., Vandevelde, S., Vanderplasschen, W., De Maeyer, J., & Vanheule, S. (2017). The concept of recovery as experienced by persons with dual diagnosis: A systematic review of qualitative research from a first-person perspective. Journal of Dual Diagnosis, 13(4), 264–279.PubMedCrossRef

De Weert, G. H., Markus, W., Kissane, D. W., & De Jong, C. A. J. (2017). Demoralization in patients with substance use and co-occurring psychiatric disorders. Journal of Dual Diagnosis, 13(2), 136–143.PubMedCrossRef

Delespaul, P., & Consensusgroep EPA (2013). Consensus regarding the definition of persons with severe mental illness and the number of such persons in the Netherlands. Tijdschrift voor Psychiatrie, 55(6):427–348.

Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., et al. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. The Lancet Psychiatry, 2(3), 233–238.PubMedCrossRef

Dom, G. (2013). Handboek dubbele diagnose. Amsterdam: Boom uitgevers.

Drake, R. E., O’Neal, E. L., & Wallach, M. A. (2008). A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. Journal of Substance Abuse Treatment, 34(1), 123–138.PubMedCrossRef

Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008). A meta-analytic review of psychosocial interventions for substance use disorders. American Journal of Psychiatry, 165(2), 179–187.CrossRef

Eggink, E., De Waal, M. M., & Goudriaan, A. E. (2019). Criminal offending and associated factors in dual diagnosis patients. Psychiatry Research, 273, 355–362.PubMedCrossRef

Essock, S. M., Mueser, K. T., Drake, R. E., Covell, N. H., McHugo, G. J., Frisman, L. K., et al. (2006). Comparison of ACT and standard case management for delivering integrated treatment for co-occurring disorders. Psychiatric Services, 57(2), 185–196.PubMedCrossRef

Flint, A. J., Meyers, B. S., Rothschild, A. J., Whyte, E. M., Alexopoulos, G. S., Rudorfer, M. V., et al. (2019). Effect of continuing olanzapine vs placebo on relapse among patients with psychotic depression in remission: The STOP-PD II randomized clinical trial. JAMA, 322(7), 622–631.PubMedPubMedCentralCrossRef

Florez, G., Saiz, P. A., Garcia-Portilla, P., Alvarez, S., Nogueiras, L., & Bobes, J. (2011). Topiramate for the treatment of alcohol dependence: Comparison with naltrexone. European Addiction Research, 17(1), 29–36.PubMedCrossRef

Franken, I., Brink, W. V., & Schellekens, A. F. (2019). Handboek verslaving. Amsterdam: De Tijdstroom/Boom Uitgevers.

Gendy, M. N. S., Lagzdins, D., Schaman, J., & Le Foll, B. (2020). Melatonin for treatment-seeking alcohol use disorder patients with sleeping problems: A randomized clinical pilot trial. Scientific Reports, 10(1), 8739.PubMedPubMedCentralCrossRef

Haney, M., Ramesh, D., Glass, A., Pavlicova, M., Bedi, G., & Cooper, Z. D. (2015). Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 40(11), 2489–2498.CrossRef

Hunter, A., Murray, R., Asher, L., & Leonardi-Bee, J. (2020). The effects of tobacco smoking, and prenatal tobacco smoke exposure, on risk of schizophrenia: A systematic review and meta-analysis. Nicotine & Tobacco Research, 22(1), 3–10.CrossRef

Kikkert, M., Goudriaan, A., De Waal, M., Peen, J., & Dekker, J. (2018). Effectiveness of Integrated Dual Diagnosis Treatment (IDDT) in severe mental illness outpatients with a co-occurring substance use disorder. Journal of Substance Abuse Treatment, 95, 35–42.PubMedCrossRef

Krause, M., Huhn, M., Schneider-Thoma, J., Bighelli, I., Gutsmiedl, K., & Leucht, S. (2019). Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use: A systematic review and meta-analysis. European neuropsychopharmacology: The journal of the European College of Neuropsychopharmacology, 29(1):32–45.

Lawrence, D., Hancock, K. J., & Kisely, S. (2013). The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: Retrospective analysis of population based registers. BMJ, 346, f2539.PubMedPubMedCentralCrossRef

Lee, S. Y., Wang, T. Y., Chen, S. L., Chang, Y. H., Chen, P. S., Huang, S. Y., et al. (2018). Add-on memantine treatment for bipolar ii disorder comorbid with alcohol dependence: A 12-week follow-up study. Alcoholism, Clinical and Experimental Research, 42(6), 1044–1050.PubMedPubMedCentralCrossRef

Liddle, H. A., Dakof, G. A., Rowe, C. L., Henderson, C., Greenbaum, P., Wang, W., et al. (2018). Multidimensional family therapy as a community-based alternative to residential treatment for adolescents with substance use and co-occurring mental health disorders. Journal of Substance Abuse Treatment, 90, 47–56.PubMedCrossRef

Martensson, S., Johansen, K. S., & Hjorthoj, C. (2019). Dual diagnosis and mechanical restraint – A register based study of 31,793 patients and 6,562 episodes of mechanical restraint in the capital region of Denmark from 2010–2014. Nordic Journal of Psychiatry, 73(3), 169–177.PubMedCrossRef

Mason, B. J. (1996). Dosing issues in the pharmacotherapy of alcoholism. Alcoholism, Clinical and Experimental Research, 20(7 Suppl), 10A–16A.PubMedCrossRef

McKelvey, K., Thrul, J., & Ramo, D. (2017). Impact of quitting smoking and smoking cessation treatment on substance use outcomes: An updated and narrative review. Addictive Behaviors, 65, 161–170.PubMedCrossRef

Miller, W. R., & Rollnick, S. (2014). Motiverende gespreksvoering: Mensen helpen veranderen. Ouderkerk aan den IJssel: Ekklesia.

Neven, A., Kool, N., Bonebakker, A. E., & Mulder, C. L. (2018). Geïntegreerd behandelen van patiënten met dubbele diagnose met integrated dual diagnosis treatment (IDDT): systematische literatuurstudie. Tijdschrift voor Psychiatrie, 60(4), 231–240.PubMed

Nuijten, M., Blanken, P., Van den Brink, W., & Hendriks, V. (2011). Cocaine Addiction Treatments to improve Control and reduce Harm (CATCH): New pharmacological treatment options for crack-cocaine dependence in the Netherlands. BMC Psychiatry, 11, 135.PubMedPubMedCentralCrossRef

Nunes, E. V., & Levin, F. R. (2004). Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis. JAMA, 291(15), 1887–1896.PubMedCrossRef

Onyeka, I. N., Collier Hoegh, M. M., Naheim Eien Em, C. M., Nwaru Bi, M. P., & Melle, I. M. D. P. (2019). Comorbidity of physical disorders among patients with severe mental illness with and without substance use disorders: A systematic review and meta-analysis. Journal of Dual Diagnosis, 15(3):192–206.

Pettinati, H. M. (2004). Antidepressant treatment of co-occurring depression and alcohol dependence. Biological Psychiatry, 56(10), 785–792.PubMedCrossRef

Reis, A. D., Castro, L. A., Faria, R., & Laranjeira, R. (2008). Craving decrease with topiramate in outpatient treatment for cocaine dependence: An open label trial. Brazilian Journal of Psychiatry, 30(2), 132–135.PubMedCrossRef

Roncero, C., Gomez-Baeza, S., Vazquez, J. M., Teran, A., Szerman, N., Casas, M., et al. (2013). Perception of Spanish professionals on therapeutic adherence of dual diagnosis patients. Actas Españolas de Psiquiatría, 41(6), 319–329.PubMed

Roncero, C., Szerman, N., Teran, A., Pino, C., Vazquez, J. M., Velasco, E., et al. (2016). Professionals’ perception on the management of patients with dual disorders. Patient Prefer Adherence, 10, 1855–1868.PubMedPubMedCentralCrossRef

Rose, J. E., Behm, F. M., Drgon, T., Johnson, C., & Uhl, G. R. (2010). Personalized smoking cessation: Interactions between nicotine dose, dependence and quit-success genotype score. Molecular Medicine, 16(7–8), 247–253.PubMedPubMedCentralCrossRef

Salloum, I. M., Cornelius, J. R., Daley, D. C., Kirisci, L., Himmelhoch, J. M., & Thase, M. E. (2005). Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: A double-blind placebo-controlled study. Archives of General Psychiatry, 62(1), 37–45.PubMedCrossRef

Satre, D. D., Leibowitz, A., Sterling, S. A., Lu, Y., Travis, A., & Weisner, C. (2016). A randomized clinical trial of motivational Interviewing to reduce alcohol and drug use among patients with depression. Journal of Consulting and Clinical Psychology, 84(7), 571–579.PubMedPubMedCentralCrossRef

Sherman, B. J., & McRae-Clark, A. L. (2016). Treatment of cannabis use disorder: Current science and future outlook. Pharmacotherapy, 36(5), 511–535.PubMedPubMedCentralCrossRef

Substance Abuse and Mental Health Services Administration (2010). Integrated treatment for co-occurring disorders evidence-based practice (EBT) kit. Rockville: SAMSHA.

Subodh, B. N., Sahoo, S., Basu, D., & Mattoo, S. K. (2019). Age of onset of substance use in patients with dual diagnosis and its association with clinical characteristics, risk behaviors, course, and outcome: A retrospective study. Indian Journal of Psychiatry, 61(4), 359–368.PubMedPubMedCentralCrossRef

Toftdahl, N. G., Nordentoft, M., & Hjorthoj, C. (2016). Prevalence of substance use disorders in psychiatric patients: A nationwide Danish population-based study. Social Psychiatry and Psychiatric Epidemiology, 51(1), 129–140.PubMedCrossRef

Torrey, W. C., Drake, R. E., Dixon, L., Burns, B. J., Flynn, L., Rush, A. J., et al. (2001). Implementing evidence-based practices for persons with severe mental illnesses. Psychiatric Services, 52(1), 45–50.PubMedCrossRef

Van Hagen, L. J., De Waal, M. M., Christ, C., Dekker, J. J. M., & Goudriaan, A. E. (2019). Patient characteristics predicting abstinence in substance use disorder patients with comorbid mental disorders. Journal of Dual Diagnosis, 15(4), 312-323.

Van Kranenburg, G. D., Van den Brink, R. H. S., Mulder, W. G., Diekman, W. J., Pijnenborg, G. H. M., & Mulder, C. L. (2019). Clinical effects and treatment outcomes of long-term compulsory in-patient treatment of treatment-resistant patients with severe mental illness and substance-use disorder. BMC Psychiatry, 19(1), 270.PubMedPubMedCentralCrossRef

Van Vugt, M. D., Kroon, H., Delespaul, P. A., & Mulder, C. L. (2014). Assertive community treatment and associations with substance abuse problems. Community Mental Health Journal, 50(4), 460–465.PubMedCrossRef

World Health Organization (2018). Management of physical health conditions in adults with severe mental disorders. Geneve: World Health Organization.

Titel: Stoornis in het gebruik van een middel
Auteurs: Drs. Maarten Belgers
Prof. dr. Arnt Schellekens
Uitgeverij: Bohn Stafleu van Loghum
Boek: Ernstige psychiatrische aandoeningen
Print ISBN: 978-90-368-2585-6

Elektronisch ISBN: 978-90-368-2586-3

Copyright: 2021
DOI: https://doi.org/10.1007/978-90-368-2586-3_15

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen